YOU STOPPED AT: Comparison: Your Classifications at Each Stage Complete Timeline of Your Risk Classification Stage...

Comparison: Your Classifications at Each Stage

Complete Timeline of Your Risk Classification

| Stage | Classification | Basis | Prognosis | BCRFS at 5 Years | |---|---|---|---|---| | Before surgery | Favorable Intermediate Risk | Gleason 3+4=7, PSA <10, cT2a | Excellent | 85-90% | | After surgery (pathology) | Favorable Intermediate Risk (Confirmed) | pT2, Gleason 3+4=7, negative margins | Excellent | 85-90% | | At 130 days (PSA 0.004 ng/mL) | Favorable Intermediate Risk (Excellent prognosis subset) | Undetectable PSA nadir, complete cancer removal | Excellent | 85-90% | | At 304 days (PSA 0.007 ng/mL) | Favorable Intermediate Risk (Stable, excellent prognosis) | Undetectable PSA, slow rise, no BCR | Excellent | 85-90% |

---

Key Insight: Your Classification Remains Stable

Why Your Risk Category Doesn't Change

According to NCCN Guidelines (2025), AUA Guidelines (2023), and EAU Guidelines (2023):

Risk classification is determined by:

• ✅ Pre-treatment factors (PSA at diagnosis, Gleason score, clinical stage)
• ✅ Pathological factors (pT stage, margins, Grade Group)
• ❌ NOT by post-treatment PSA values

Your classification has remained "Favorable Intermediate Risk" throughout because:

1. Your Gleason score is 3+4=7 (Grade Group 2)

   • This is the PRIMARY determinant of your risk category
   • It doesn't change after surgery
   • It defines you as "intermediate risk"

2. Your pathological stage is pT2 (organ-confined)

   • Cancer stayed within the prostate
   • No extraprostatic extension
   • This is "favorable"

3. Your surgical margins are negative (close apical, not positive)

   • Complete cancer removal achieved
   • Excellent surgical outcome
   • Supports "favorable" classification

Result: Favorable Intermediate Risk — and this classification is STABLE

---

What Changes: Your Prognosis Within That Classification

Your Risk Category Stays the Same, But Your Prognosis Improves

Important distinction:

| Concept | Definition | Your Status | |---|---|---| | Risk Classification | Cancer biology and stage at diagnosis | ✅ Favorable Intermediate Risk (STABLE) | | Prognosis | Predicted outcome based on all factors | ✅ Excellent (improving with each undetectable PSA) | | PSA nadir | Reflects surgical quality, not cancer biology | ✅ 0.004 ng/mL (excellent) | | PSA trajectory | Reflects treatment response over time | ✅ Undetectable, slow rise (reassuring) |

Your prognosis is excellent BECAUSE:

• ✅ Your risk classification is favorable intermediate (not high-risk)
• ✅ Your PSA nadir is excellent (0.004 ng/mL)
• ✅ Your PSA remains undetectable at 10 months
• ✅ Your PSA doubling time is slow (~9-10 months)
• ✅ You have no biochemical recurrence

Source: NCCN Guidelines for Prostate Cancer (2025) — Risk stratification and prognostic factors; AUA Guidelines (2023) — Prognosis after prostatectomy; EAU Guidelines (2023) — Risk classification and outcomes

---

Your Prognosis by the Numbers

5-Year and 10-Year Outcomes for Favorable Intermediate Risk Patients

For patients with your characteristics (pT2, Gleason 3+4=7, undetectable PSA):

| Outcome | 5 Years | 10 Years | Your Likelihood | |---|---|---|---| | Biochemical Recurrence-Free Survival (BCRFS) | 85-90% | 75-80% | ✅ Excellent | | Metastasis-Free Survival | 95-98% | 90-95% | ✅ Excellent | | Prostate Cancer-Specific Survival | 98-99% | 95-98% | ✅ Excellent | | Overall Survival | 95-97% | 85-90% | ✅ Normal life expectancy |

What this means:

• ✅ 85-90% chance you'll remain free of biochemical recurrence at 5 years
• ✅ 95-98% chance cancer won't spread to distant sites at 5 years
• ✅ 98-99% chance prostate cancer won't be life-limiting at 5 years
• ✅ Your life expectancy is normal (prostate cancer unlikely to be the cause of death)

Source: NCCN Guidelines for Prostate Cancer (2025) — Outcomes for favorable intermediate risk prostate cancer; AUA Guidelines (2023) — Long-term prognosis after prostatectomy; EAU Guidelines (2023) — Prognostic factors and survival

---

What Happens If PSA Rises Further?

Biochemical Recurrence: Definition and Management

If your PSA continues to rise and crosses the threshold:

Definition of Biochemical Recurrence (BCR):

• PSA rises above 0.1 ng/mL after being undetectable, OR
• PSA rises on two consecutive tests above 0.1 ng/mL

You do NOT currently have BCR because:

• ✅ Your PSA is 0.007 ng/mL (well below 0.1 ng/mL)
• ✅ You only have one rising value (not two consecutive)
• ✅ Your PSA doubling time is slow (~9-10 months)

If BCR is confirmed (PSA >0.1 ng/mL):

According to NCCN Guidelines (2025), AUA Guidelines (2023), and EAU Guidelines (2023):

Your salvage therapy options would include:

1. Salvage Radiation Therapy (Most Common)

   • ✅ Recommended if PSA <0.5 ng/mL
   • ✅ 50-70% chance of long-term PSA control
   • ✅ Best outcomes when PSA is low at time of treatment

2. Salvage Hormone Therapy (ADT)

   • ✅ Recommended if PSA >0.5 ng/mL or imaging shows metastases
   • ✅ Can be combined with radiation therapy
   • ✅ Delays progression but doesn't cure

3. Clinical Trials

   • ✅ Novel therapies for BCR
   • ✅ Discuss with your oncologist

Important: BCR does NOT mean your cancer has returned to your body. It means PSA is detectable again, which requires further investigation and possible treatment.

Your advantage: If BCR occurs, your slow PSA doubling time means you'll have time to plan treatment before PSA becomes very high.

Source: NCCN Guidelines for Prostate Cancer (2025) — Management of biochemical recurrence; AUA Guidelines (2023) — Salvage therapy options; EAU Guidelines (2023) — Treatment of recurrent prostate cancer

---

Your Monitoring Plan: Next Steps

Recommended Follow-Up Schedule

According to NCCN Guidelines (2025), AUA Guidelines (2023), and EAU Guidelines (2023):

For favorable intermediate risk patients with undetectable PSA and slight rise:

| Time Point | Recommended Action | Your Status | |---|---|---| | Now (304 days post-op) | PSA = 0.007 ng/mL | ✅ Undetectable, stable | | **In 3 months